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ABSTRACT
Effects of the MTHFR C677T allele on reproduction include multiple complications. The
frequency of births with neural tube defects, Down Syndrome, or recurrent pregnancy loss of
CC, CT, and TT mothers was measured using data collected from existing literature. Total
participants n=2605 (n=1111 cases, n=1494 controls). Results show that folic acid
supplementation did not prevent the incidence of NTD pregnancy in CT women. Furthermore,
CT women are more fecund overall, producing more pregnancies than CC and TT women. While
CT case women did have higher incidences of RPL, NTD pregnancy and DS pregnancy, this is
due to the overall greater number of pregnancies. This higher fecundity may be the natural
selective mechanism explaining the high frequency of this otherwise negative polymorphism.

vi

LITERATURE REVIEW & THEORY
Introduction
The methylenetetrahydrofolate reductase (MTHFR) gene controls the metabolism of
homocysteine into methionine and is an imperative part of 1-carbon metabolism (Friso et al.,
2002). The C677T mutation is a single nucleotide polymorphism (SNP) at the 677th position
which has been studied extensively since its discovery in the 1990s. The SNP is associated with
deleterious health effects and negative effects on reproduction, and was first reported in Eurasian
populations. Since then, high frequencies of the mutation have been reported in East Asian
countries, the Mediterranean, Western Europe, Mexico, and Central America. This paper will
review the known effects of the mutation and its geographic spread, and the evolutionary theory
and hypotheses regarding its ongoing selection.
Later, I will quantify the mutation’s response to natural selection by calculating
differential fertility using previously collected data regarding the birth outcomes of women with
the C677T mutation. Data was collected in cases where women with the C677T mutation gave
birth to a child with Down Syndrome or neural tube defects, or in instances where women who
suffered with RPL were able to conceive. By calculating how the T-allele influences pregnancy
outcome, this aspect of the phenotypic response to natural selection can be quantified. This is
first and foremost an evolutionary question. I wish to assist in finding the reason that allows this
allele to continue to maintain its frequency in populations.
Furthermore, the populations which report the highest frequencies of the mutation are
also the populations that are the least studied. These central American populations are commonly
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Native and Indigenous populations in states of epidemiological transition. Clinical literature
habitually omits populations that are not able to be reached through biomedical practitioners,
either through physical distance or monetary disparity. Moreover, the literature frequently
disregards the role of women in pregnancy and delivery, focusing instead on the fetus and the
outcome of the birth. The goal of this project is to determine the role of genotype in determining
the outcome of a birth (in regard to neural tube defects and Down Syndrome births) or the ability
to conceive (in regard to recurrent pregnancy loss), and to demonstrate the need for research that
combines reproductive justice theory, a framework that advocates for Native and Indigenous
sovereignty, evolutionary genetics, and bioanthropology. Applied anthropology is a field that is
simultaneously interdisciplinary and designed to incorporate theory into action. Our discipline is
uniquely prepared to meet the needs of this research gap.

Biochemistry
The 5,10-methylenetetrahydrofolate reductase (MTHFR) enzyme is a crucial part of the
1-carbon cycle, as it is responsible for the conversion of 5,10-methylenetetrahydrofolate to 5methyltetrahydrofolate (Liew & Gupta, 2015). 5-methylTHF is the principal circulatory folate
present in the body and is the main methyl donor for the recycling of homocysteine to
methionine, a predecessor to S-adenosylmethionine (SAM, a universal methyl donor). Not only
is this step important for the continuation of one carbon metabolism, but it is also crucial to keep
homocysteine levels low due to its innate toxicity. Failure to produce an adequate amount of
methyl groups results in an abundance of total serum homocysteine and S-adenosylhomocysteine
(SAH), an inhibitor of methylation reactions (Nazki et al., 2014).
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This role in methyl group synthesis is also instrumental to epigenetic DNA methylation.
The methionine produced by the re-methylation of homocysteine by 5-methylTHF is a substrate
for SAM, which is the primary universal methyl donor responsible for DNA methylation
processes. The production of methyl donors through one carbon metabolism is the principal
source for methylation reactions conducted by SAM. DNA and histone methylation are crucial to
cell maintenance: DNA repair, membrane transport, gene and chromosome inactivation and
regulation are all functions facilitated through methylation processes. Abnormal or reduced
epigenetic methylation has long been associated with carcinogenesis and neurological diseases.
Furthermore, methyl tags are imperative to embryonic development and are heritable. Proper
methylation is highly influential to trophoblast growth, imprinting, and epigenesis (Clement et
al., 2020; Menezo et al., 2016). After being erased early in embryonic development, inherited
methyl tags are reinstated in postnatal follicular development in females and in prenatal life in
males (Servy et al., 2018).

Figure 1. Folate and 1-Carbon cycle interaction. Reused from (Servy et al., 2018).The copyright disclosure can be found in
Appendix A.

The MTHFR C677T mutation is found on the MTHFR locus on chromosome 1 and
occurs due to a single nucleotide substitution at the 677th position. This substitution results in an
3

amino acid change from alanine to valine, which codes for a thermolabile variant of the MTHFR
enzyme where performance is hindered above 37° Celsius. It is estimated that at 37° Celsius,
MTHFR activity in homozygous individuals is reduced by 50-60% compared to wild-type
individuals, while increased body temperature causes further reduction in performance (Liew &
Gupta, 2015). In heterozygous individuals, the reduction of enzymatic performance is reported at
varying levels; due to the co-dominant nature of the mutation, heterozygous individuals
experience a lessened reduction in enzymatic function.
Such a reduction in enzymatic performance prevents the recycling of homocysteine into
methionine. The accumulation of homocysteine can result in hyperhomocysteinemia, a condition
associated with neural tube defects, cardiovascular disease, uteroplacental circulation, recurrent
pregnancy loss, thrombosis, deficient cell division, and the production of inflammatory cytokines
(Félix et al., 2004; Friso et al., 2002; I. W. Hwang et al., 2017; K. R. Hwang et al., 2017; R. M.
Lee et al., 2004; Liew & Gupta, 2015; Nair et al., 2012; Sukla & Raman, 2012). In addition to
hyperhomocysteinemia, individuals with the T-allele will also experience a reduction in the
amount of 5-methyltetrahydrofolate. Servy and colleagues estimate this decrease in 5methylTHF generation by 17-75% compared to the amount of 5-methylTHF converted in
individuals with the wild-type allele.
As 5-methylTHF is the primary circulatory folate in the body, its diminution likely
affects fecundity, embryonic growth and development, and the mitigation of congenital defects.
Low levels of 5-mythlTHF can also lead to DNA hypomethylation and increased risk of DNA
strand breakage, due to the role of methylenetetrahydrofolate in thymidylate synthesis.
Decreased thymidylate synthesis often causes the misincorporation of uracil, which can lead to
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DNA strand breakage and chromosomal breakage (Nazki et al., 2014). Folate deficiency
additionally decreases the efficacy of the conversion of homocysteine to methionine.
Because fewer methyl groups are synthesized, homocysteine accumulation further
inhibits the methylation process. Such an accretion of homocysteine can instigate abnormal and
reduced DNA methylation by decreasing the amount of available methionine (and SAM), which
has long been associated with carcinogenesis and neurological diseases (Friso et al., 2002; Servy
et al., 2018; Tang et al., 2014). While it is currently recommended that pregnant women take a
supplemental form of folic acid and is sometimes effective in meeting the adequate level of
folates required, such a dose is not always a sufficient treatment for women with the MTHFR
C677T allele. In fact, it can be harmful (Clément et al., 2020; Servy et al., 2018).
Synthetic folic acid must be metabolized into tetrahydrofolate prior to being methylated
to 5,10 MTHF and then converted to 5-methylTHF (Figure 1). Both of these actions are difficult
to complete for individuals with the T-allele; though the mechanism is unknown, heterozygous
and (to a greater extent) homozygous individuals do not easily metabolize synthetic folates to
tetrahydrofolate (THF) (Servy et al., 2018). Furthermore, any metabolized THF that enters the 1carbon cycle is not easily converted later from 5,10-MTHF to 5-mthylTHF due to the
thermolabile MTHFR enzyme. When left to accrue, this can develop into unmetabolized folic
acid syndrome (UMFA), a harmful side effect due to its disruption of immune function and
potential to trigger tumorigenesis.
Moreover, UMFA increases homocysteine circulation and the accumulation of folic acid
blocks both dietary-derived methylfolate and 5-mthylTHF from entering the 1-carbon cycle
(Clement et al., 2020). It has recently been suggested that supplementation with 5-mthylTHF
itself is more effective for CT and TT individuals than synthetic folic acid, though the latter
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remains the conventional recommendation (Clement et al., 2020; Servy et al., 2018).
Furthermore, testing for the MTHFR C677T mutation is not commonly done prior to the
detection of fertility problems, meaning that the typical woman endeavoring to conceive is
unaware of the potential harm of folic acid supplementation.

Health Effects
The majority of research conducted on the effects of the C677T mutation have taken
place in Europe and Asia. Nevertheless, the effects of the mutation remain largely unstudied in
populations outside Eurasia. The available literature show that the mutation is associated with a
number of adverse effects ranging from vascular disorders, neurological ailments, psoriasis,
psychiatric disorders, multiple forms of cancer, and a number of adverse effects on pregnancy
and fertility. (J. Chen et al., 1996a; Hernández-Vásquez et al., 2017; Lykke et al., 2012;
Michalek et al., 2017; Stonek et al., 2007; Yang et al., 2014; D. Zhang et al., 2015).
Cardiovascular disease, coronary artery disease, and arterial hypertension have all been
associated with hyperhomocysteinemia, an effect that commonly occurs with the MTHFR
C677T mutation due to its effect on 1-carbon metabolism (Nazki et al., 2014). A phenotypic
increase in the levels of circulatory homocysteine due to the MTHFR C677T mutation has also
been linked to migraine with auras. Homocysteine can perform as a stimulant amino acid in the
pathophysiology of migraines, instigating a temporary thrombotic event or vasodilation of
cerebral vasculature, thus diminishing the amount of oxygen able to reach the brain and allowing
the migraine to occur (A. Liu et al., 2010). It is also suggested that migraine susceptibility is
enhanced in individuals with the T-allele due to vascular endothelial dysfunction, which can
activate fibers of the trigeminal nerve (A. Liu et al., 2010).
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These pathways leading to migraines ultimately rely on an upstream event of
hyperhomocysteinemia in order to activate downstream neurological symptoms witnessed in
individuals with migraines with aura. While many repeated studies have found an association
between migraine with aura and the MTHFR C677T allele in young and middle-aged adults,
some report that no association exists in older populations though this may be due to selective
survival as both phenotypes are associated with lowered longevity (Scher et al., 2013). Similarly,
increased homocysteine, decreased methionine (and therefore, decreased methylation), and
anomalous folate circulation have also been associated with tumorigenesis and carcinogenesis as
well as numerous types of cancer (Tang et al., 2014). Due to folate’s role in nucleotide synthesis,
individuals with lower measures of circulating folate due to the MTHFR C677T mutation may
also experience increased double-strand breaks in DNA which further increases cancer risk
(Stumbryte et al., 2018).
In a meta-analysis of over thirty-five thousand individuals, high homocysteine coupled
with low folate was associated with increased risk of carcinogenesis overall and showed
heterozygous advantage. Cancer risk was only associated with homozygous TT individuals and
homozygous wild-type CC individuals (D. Zhang et al., 2015). Tang and colleagues found that
Asian individuals are at higher risk of developing cancer in general, though rates of stomach and
esophageal cancer are particularly high among this demographic group (Tang et al., 2014). This
association was later confirmed in Chinese populations after another meta-analysis found
increased risk of development of esophageal cancer, and again in the Han Chinese ethnic group
when the polymorphism was significantly associated with risk of esophageal squamous cell
carcinoma in individuals with low serum circulatory folate (Huang et al., 2013; Yang et al.,
2014).
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The mutation has been found to be a strong risk factor for stomach cancer in Chinese
populations, but this risk is not duplicated in other populations (Nazki et al., 2014). In lung
cancer patients, CT individuals with Stage III or Stage IV cancer have a lower rate of survival
than earlier stage patients (Stumbryte et al., 2018). CT and TT individuals were also shown to
have a more rapid disease progression to death in patients with non-small-cell lung cancer
(Alberola et al., 2004; Hong et al., 2013). The wildtype CC genotype was also found to have a
better response to gemcitabine/platinum chemotherapy, which is one of the most commonly used
treatment regiments for patients of non-small-cell lung cancer. This is again due to the lowered
efficacy of DNA methylation under the conditions of the mutant T-allele (Hong et al., 2013).
Other treatments, such as a combination of pemetrexed with pemetrexed plus carboplatin have
shown to be much more effective for carriers of the T-allele, and can significantly lengthen the
period of progression-free survival (Smit et al., 2009; Tiseo et al., 2012).
The association of the mutation with risk of colorectal cancer and leukemia has also been
examined expansively. These have returned population-dependent results, with no consistently
recurring patterns across multiple populations. Acute lymphoblastic leukemia (ALL) was found
to have no association with the mutation in two Brazilian populations nor in two Western
European populations but was found to be associated with the mutation in a Korean population
(Nazki et al., 2014). Three more studies (one in a Greek population and two in Brazilian
populations) found that the mutation decreased the risk of developing leukemia (Nazki et al.,
2014). In the case of colorectal cancers, methyl status may also play a role in these inconsistent
results. If folate is high in combination with low methyl levels, risk of cancer may be lower.
However, if folate is low in combination with low methyl, the risk of colorectal cancer is
increased (J. Chen et al., 1996b; Ma et al., 1997).
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The risk of head and neck carcinogenesis may only be associated with the MTHFR
C677T mutation when alcohol abuse is involved, but there is variance in the reported level of
abuse required to observe such an association (Nazki et al., 2014).The mutation has also been
associated with an increased risk of schizophrenia (Muntjewerff et al., 2006). In a meta-analysis
of eighteen studies, Zhang and colleagues found that homocysteine levels at or above 5 µmol/l is
associated with a 70% increase risk of developing schizophrenia. The homozygous TT genotype
was also found to carry a 36% higher risk of developing schizophrenia over the wild-type CC
genotype (Yanling Zhang et al., 2013). Psoriasis has also been found to be associated with the
mutation as a result of the hypomethylation seen in individuals with the T-allele (Liew & Gupta,
2015). However, this pattern of association has only been found in Chinese and Czech
populations, and was not repeated in Austrian or Malaysian populations (Liew & Gupta, 2015;
Vasku et al., 2009).
Most recently, it has been theorized that individuals with the MTHFR C677T mutation in
a state of hyperhomocysteinemia suffer more severe health outcomes from the COVID-19 virus
(Karst et al., 2020). Karst and colleagues hypothesize that the health outcomes associated with
the C677T mutation such as hyperhomocysteinemia, atherosclerosis, and hypertension all worsen
COVID-19 outcomes. Furthermore, they postulate that worldwide differences in severity of the
disease can be attributed to the mutation as well. Countries like Italy, China, and the UK have
well-documented, high frequencies of the C677T polymorphism and also faced some of the most
severe epidemiological consequences of the pandemic. No clinical study has been conducted on
this relationship between the mutation, homocysteine levels, and COVID-19 severity yet due to
the ongoing nature of the pandemic. It is recommended for now that homocysteine levels are
assessed in patients facing severe symptoms from the COVID-19 virus (as this is less time-
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consuming than genetic testing for the mutation) and dietary changes are made in patients with
hyperhomocysteinemia (Karst et al., 2020).

Effects on Reproduction
Different aspects of reproduction in men and women have been reported to be affected by
the MTHFR C677T mutation. Due to hypomethylation and reduced folate, the mutation has been
associated with male and female infertility (Milenkovic et al., 2020; Tara et al., 2015; Turgal et
al., 2018; Vani et al., 2012), recurrent pregnancy loss (Mukhopadhyay et al., 2009; Wolski et al.,
2017; Xu et al., 2019) spontaneous abortion (Stangler Herodež et al., 2013; Zetterberg et al.,
2002), thrombophilia (Karakantza et al., 2008; Mehandjiev et al., 2019), pre-term birth (Hiltunen
et al., 2011; Tiwari et al., 2015), low birth weight (H. A. Lee et al., 2013; Wu et al., 2017), poor
outcomes with assisted reproductive treatment (ART) (Enciso et al., 2016), chromosomal
abnormalities such as Down Syndrome (Kedar & Chandel, 2019; Vraneković et al., 2010),
pregnancy complications (Lykke et al., 2012; Pogliani et al., 2010; Sultana et al., 2020), and
congenital defects including congenital heart defects (Z. Li et al., 2015; Zidan et al., 2013) and,
perhaps most notably, neural tube defects (NTD) (Blom et al., 2006; Van Der Put & Blom, 2000;
Y. Wang et al., 2015b).
Male infertility was found to be associated with the T-allele in population specific
studies, though this has not been replicated in all instances of study. In an Iranian population,
low semen quality was associated with both the CT and TT genotypes, and it was observed that
supplementation with vitamin B12 can restore the quality of sperm (Najafipour et al., 2017).
Another Iranian study found that hypomethylation due to presence of the MTHFR C677T
mutation male partners can cause recurrent miscarriage (Tara et al., 2015). This association
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between low semen quality and the T-allele was replicated in a Chinese population and is
thought to be due to hyperhomocysteinemia (L. Liu et al., 2012). Again in a North Indian
population, the presence of the T-allele increased the risk of male infertility two-fold, where the
mechanism was postulated to be hypomethylation due to the importance of methylation in
spermatogenesis (Naqvi et al., 2014).
Hyperhomocysteinemia has also been considered as the mechanism behind MTHFR
C677Tand male infertility in Indian populations (Dhillon et al., 2007; Ferlin et al., 2007).
However, no association was found in a South Indian population, nor in the Netherlands (Ebisch
et al., 2003; Vani et al., 2012). General infertility in female patients has also been reported in
association with the MTHFR C677T mutation. In a case-control study of 225 females with
unexplained infertility undergoing in-vitro fertilization, the T-allele was significantly associated
with unexplained infertility (Milenkovic et al., 2020). Difficulty getting pregnant through
assisted reproductive treatment (ART) has also been reported in couples with the C677T
polymorphism.
Other infertility problems in women such as recurrent pregnancy loss and spontaneous
abortions have also been reported in association with the MTHFR C677T mutation, however the
mechanism causing the observed outcomes remain unknown (Mehandjiev et al., 2019). The
mutation was found to be significantly associated with recurrent pregnancy loss in an
endogamous North Indian population, a highly heterogenous North Indian population, a metaanalysis representing the broader Chinese population, and in a central Eastern Chinese
population (H. Chen et al., 2016; Mukhopadhyay et al., 2009; Nair et al., 2012; Xu et al., 2019).
Conversely, no association with recurrent pregnancy loss was found in a Yamato Japanese
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population, a Polish population, and the South Korean population (K. R. Hwang et al., 2017;
Makino et al., 2004; Wolski et al., 2017).
Spontaneous abortion is not as widely investigated in the absence of other fetal
concomitant pathologies, nonetheless it was significantly associated with the T-allele in a
Slovenian population. However, it was discovered that male probands with heterozygote or
homozygous C677T mutations primarily contribute to the spontaneous abortion event (Stangler
Herodež et al., 2013). A Swedish study found the composite presence of the C677T and MTHFR
A1298C mutation increased the risk of spontaneous abortion by 14 times due to the impact of
hyperhomocysteinemia (Zetterberg et al., 2002). Deciduous and intervillous thrombophilia
pathologies have also been examined in cases of pregnancy loss.
In a Japanese study of 243 patients, an association between the CT and TT genotypes was
found present with thrombophilia leading to pregnancy loss (Mehandjiev et al., 2019). Advanced
thrombophilic pathologies that lead to spontaneous abortion are thought to be related to
hyperhomocysteinemia, as high methionine levels are needed for proper tissue growth in early
stages of development (Mehandjiev et al., 2019). Thrombophilia and homocysteine levels were
again linked to the mutation in a Greek population where the presence of the homozygous TT
genotype resulted in the increased risk of placental abruption by 4.8 times even with normal
folate levels, and folate and vitamin B12 supplementation (Karakantza et al., 2008).
Difficulty to conceive has also led individuals with the MTHFR C677T mutation to seek
ART. Heterozygous individuals were found to be overrepresented within the pool of subfertile
patients seeking ART in a German population due to recurrent miscarriage or failure of embryo
implantation, and homozygous TT individuals were significantly associated with failure to
implant healthy embryos without chromosomal abnormalities under care of ART (Enciso et al.,
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2016). In a Swedish study examining pregnancy outcomes following IVF, there was no
association between heterozygosity or homozygosity and successful pregnancy outcome
suggesting that pregnancy is not dependent on these MTHFR variations in the study population
(Murto et al., 2015). Folic acid supplementation also played no role in determining successful
pregnancy outcome, regardless of MTHFR C677T genotype, which indicates alternative folate
supplementation strategies may provide a better substitute for achieving pregnancy (Murto et al.,
2015).
After conception, other pregnancy complications may also impede the gestation of
women with the MTHFR C677T mutation. In a North Indian population, severe pre-eclampsia
has been significantly associated with the MTHFR C677T variant, and a 4 times greater risk of
developing pre-eclampsia was found when the T-allele is present (Sultana et al., 2020). A large
meta-analysis also reported that this connection was present between pre-eclampsia and the
C677T mutation in European and East Asian populations (X. M. Wang et al., 2013). Results of
the Danish Birth Cohort study also chronicle a significant association between the mutation and
severe pre-eclampsia in the Danish population (Lykke et al., 2012). These studies cite
hyperhomocysteinemia and oxidative stress caused by the mutation as the driving force behind
the pre-eclamptic phenotype. Contrarily, the C677T mutation was associated with a decreased
risk of developing pre-eclampsia during gestation in a Mexican Maya-Mestizo population (Canto
et al., 2008). This again suggests geographically localized selection and adaptation to the effects
of the mutation.
Congenital anomalies and defects have also been observed in association with the
MTHFR C677T mutation. In the Korean population, pre-term birth was significantly associated
with the mutation, however this result was not repeated amongst the pre-term births of the
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Finnish Birth Cohort study (Hiltunen et al., 2011; I. W. Hwang et al., 2017). In a northeast Indian
population, pre-term delivery and low birth weight were both significantly associated with the
mutation (Tiwari et al., 2015). Pre-term birth is one of the most common contributors to infant
mortality, holds substantial consequences for long-term adverse health and cognition outcomes,
and also places a heavy financial burden on families due to cost of neonatal care. Low birth
weight is also a determinant of long-term health and a leading cause of infant mortality (Tiwari
et al., 2015).
The etiology of the relationship between pre-term birth or low birth weight and the
MTHFR C677T mutation is largely unknown due to the multifactorial and complex nature of the
pathologies. However, an Indian study and a separate Korean study both performed Mendelian
randomization analysis investigating the causality between maternal homocysteine
concentration, maternal C677T genotype, and offspring birth weight. Each found that maternal
genotype predicts homocysteine level and furthermore, that the T-allele predicts higher
homocysteine concentration and lower birth weight (H. A. Lee et al., 2013; Yajnik et al., 2014).
Maternal genotype has also been found to increase risk of congenital heart disease (CHD) in a
central-eastern Chinese population and a North Egyptian population (Z. Li et al., 2015; Zidan et
al., 2013). Congenital heart disease, including all of the arrays of malformations that constitute
this diagnosis, is of polygenic inheritance and therefore its connection with the C677T mutation
is not completely elucidated. It is hypothesized that hyperhomocysteinemia may be a leading
factor in CHD (Zidan et al., 2013).
Perhaps the two most commonly occurring birth outcomes associated with the MTHFR
C677T mutation are Down Syndrome and neural tube defects. Down syndrome is the most
frequently occurring chromosomal abnormality, resulting in an additional 21st chromosome as
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indicated by its clinical name, Trisomy 21. In about 95% of cases, this additional chromosome
results from maternal non-disjuncture, a malfunction in chromosome segregation during meiosis
which transpires prior to conception in oocyte maturation (Kedar & Chandel, 2019). Part of the
etiology of this process may rely on proper folate metabolism, leading to the interest in the
investigation of the MTHFR C677T mutation. This proposed etiology and association were
found in two Indian populations and an Italian population, though no association between the
C677T mutation and Down Syndrome was found in a Croatian population (Kedar & Chandel,
2019; Rai et al., 2006; Scala et al., 2006; Vraneković et al., 2010).
The relationship between the C677T mutation and the formation of NTD is thought to be
due to the mutation’s role in folate metabolism and increased homocysteine as well. In China,
both the heterozygous CT and homozygous TT genotypes are risk factors for developing NTD
pregnancy (Y. Wang et al., 2015b; Yan et al., 2012; Zhang et al., 2019). The homozygous TT
genotype was also found to confer risk of NTD in an Indian population (Deb et al., 2011). In
Turkey, the C677T mutation alone was not associated with risk of NTD; in combination with the
other common MTHFR mutation, the A1298C polymorphism, there was an increased risk of
NTD, however (Boduroǧlu et al., 2005).
Moving east into Europe, similar findings were reported in an English population where
it was found that the combined C677T and A1298C genotypes were associated with significant
risk of NTD pregnancy development (Caroline L. Relton et al., 2004). In a different English
population, however, C677T alone was significantly associated with the risk of NTD pregnancy
(C. L. Relton et al., 2004). An association between the MTHFR C677T mutation and NTD was
found in the Netherlands, and was attributed to elevated homocysteine (Van Der Put & Blom,
2000). Though the studies were exclusive to pregnancies resulting in spina bifida, no association
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with the mutation was found in a German population (Koch et al., 1998), but an association
between the mutation and spina bifida was found in an Italian population (De Franchis et al.,
1998). In France, the C677T mutation was reported as a small risk factor for the development of
NTD pregnancies, although it was noted that folate level was more of a determinant than
genotype (Candito et al., 2008). This same conclusion was drawn in a European-descendant
population in Canada (Christensen et al., 1999). In the highly homogenous Irish population, both
the CT and TT genotypes are associated as significant risk factors for the development of NTD
(Kirke et al., 1996, 2004).
Very little study on the relationship between the C677T mutation and NTD has been
completed in Central and South America. While no association between the mutation and NTD
were found in Mexican Mestizo parents (Dávalos et al., 2000), it appears that the mutation’s
contributions to hyperhomocysteinemia and low B12 levels do effect NTD risk in Brazil (Félix et
al., 2004). Considering the very high levels of the mutation in Mexico and Central America, and
the very high prevalence of NTD in these areas (Dávalos et al., 2000), this is a relationship that is
worth much further exploration.

Distribution of the Allele and Natural Selection
Much of the origins, historical population frequency, and spread of the mutation remains
widely unknown. Based on publicly available ancient genome data from the Population
Genomics and Genetics Single Nucleotide Variant database (www.pggsnv.org), the mutation
does not appear to be present in Neanderthal or Denisovan populations and is not recorded in the
modern human genome until 7000 BC (unpublished data, Liu et al. 2021). However, very little
ancient DNA data is publicly available, and much of the accessible data is from European
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populations. It is probable that the evolutionary force primarily responsible for the modern
frequency of the mutation is natural selection, as it is found repeatedly in multiple large
populations.
In modern populations, the C677T mutation is virtually absent in Native populations of
Africa, the South Pacific, and South India. There are very few studies on the populations of
South America, the USA, and Canada. High frequencies clustered in the native peoples of
Europe, North-East Asia, the Middle East, the Mediterranean, Mexico, and Central America. All
of these former listed regions with the exception of Central America and Mexico have repeatedly
reported frequencies ranging from 20-40%, with some populations sometimes measuring
frequencies above 40%. Much more recently and to a far lesser extent, the range and effect of the
mutation has begun to be measured in Mexico and Central America. While there are now a
variety of studies which list allele frequency in Mexico and Central America ranging between
45-90%, research in this geographical area began much later than in Eurasia and the clinical
manifestations of the allele remain widely unstudied (Reyes et al., 2021).
Though the frequency of the mutation is high in both European and Native and
Indigenous groups of the New World, it is unlikely that the mutation was first introduced during
colonial times. Prior to colonization, the C677T mutation was already in high frequency in
Central and South American populations, though the A1298C variant may have been introduced
in this way (Binia et al., 2014). It is possible, however, that the effect of colonization impacted
the frequency of the mutation. It has been hypothesized that a bottleneck event occurred during
and after initial colonization due to the devastation of Native and Indigenous populations from
afflictions such as measles, smallpox, and influenza (Contreras-Cubas et al., 2016).
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Natural Selection Hypotheses
Because of the numerous deleterious health effects and potentially detrimental effects on
fertility (and therefore, evolutionary fitness), it is astounding that the C677T mutation remains so
widespread in human populations. For that reason, research groups have searched for evidence of
selective advantage in the populations where the allele is found in high frequencies. This has led
to an abundance of hypotheses as to the origin, increase, and sustainment of the allele frequency
around the world. These hypotheses include evidence of heterozygote advantage by way of
enhanced cognition performance in elderly Chinese individuals (Tsai et al., 2011), homozygote
advantage of TT fetuses of mothers receiving supplemental folate (Mayor-Olea et al., 2008a),
heterozygote advantage in survival of chemotherapy due to heightened abilities to process heavy
metals (Cui et al., 2011; Krawczyk et al., 2014; X. Li et al., 2014), and homozygous advantage
when adequately consuming folate by way of lower risk of developing acute lymphoid leukemia
(Robien & Ulrich, 2003). More general hypotheses include an increase in the T-allele due to
gene-environment interaction (Lucock et al., 2012), UV-B radiation as the selective force of
natural selection rather than UV-A radiation (Lijun et al., 2012), and the ability to normally
metabolize homocysteine notwithstanding a thermolabile enzyme in the presence of a folate-rich
diet (Ojeda-Granados et al., 2017).
Canto and colleagues found that in Maya-Mestizo women in particular, the presence of
the T allele reduces the risk of preeclampsia, resulting in more completed pregnancies and fullterm births and therefore, increasing the chance of passing the mutation to the future generation
(Canto et al., 2008). In Native and Indigenous populations within Mexico, Binia and colleagues
also found that carriers for the MTHFR C677T mutation may have better blood pressure control
with vitamin B12 supplementation, a finding that is notable due to the increasing rate of
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hypertension in Mexico (Binia et al., 2014). Some clinical studies show beneficial associations
between the mutation and enhanced chance of survival from disease for heterozygous
individuals, such as one paper showing that CT individuals have protection against chronic HBV
infection amongst young West African adults in Benin and Togo (Bronowicki et al., 2008).
These proposals are typically population specific, and do not demonstrate a universal
benefit. It is possible that due to the widespread geographic frequency of the allele, the mutation
may favor local specialization of benefits within different populations. I hypothesize that natural
selection is the active evolutionary force working upon the allele. While both natural selection
and genetic drift are forces that may lead a population to derive a high frequency of a mutation,
the MTHFR C677T mutation is found in multiple large populations across multiple continents
and is a balanced polymorphism, which suggests that the force at work here is natural selection.
It should also be clarified that natural selection will not allow a deleterious allele to continue in
high frequency unless the allele bestows a beneficial phenotype where it evolved. In short, some
(currently unknown) factor of the phenotype bequeathed by this mutation must be considered
beneficial in order for natural selection to maintain its presence.
Orr defines fitness as the ability of an organism, population, or species to survive and
reproduce within the environment they find themselves in to pass on genetic material to future
generations (Orr, 2009). Change in fitness in response to natural selection requires that some of
the differences in fitness must be due to genetic content. In this case, the genetic basis is known,
and it is likely that natural selection is occurring, but the response to natural selection has not yet
been measured. The purpose of this project is to detect natural selection operating via differential
selection of the three genotypes in women throughout the world. We will do this considering the
participants’ age and folate consumption.
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MATERIALS AND METHODS
IRB Approval
I requested approval for this project from the USF IRB board. The study was given the
number 002190 and was determined not to meet the specifications of human-subject research. I
include the letter stating that this project is not human research in Appendix C.

Data Collection
To test the null hypothesis that genotypes do not affect reproductive outcome, previously
collected data were gathered using a scoping review methodology primarily through Web of
Science, accessed through the USF Library system. Previously collected data from peerreviewed, case-control studies concerning pregnancy complications, birth outcomes, and fertility
of women with and without the MTHFR C677T mutation were obtained through a number of
search terms yielding a total of eighty-eight articles (Figure 2). A secondary search by title of the
reference sections of these eighty-eight articles yielded an additional twenty-three studies,
bringing the total to one hundred and ten articles. Inclusion criteria designated that each study
must include the maternal genotype, maternal age, folate supplementation status of the
participants (by vitamin/supplement of synthetic folic acid, dietary intake, or both if applicable),
and the birth outcome of each offspring listed by maternal genotype.
Thirty-five articles were removed from the original list due to missing one or more
relevant variables, twenty-seven were removed for not listing or being related to a birth outcome,
twelve were removed for using previously published data, three articles were removed for having
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Figure 2: Data Selection Methodology

a case group with mixed birth outcomes, two were removed for listing combined frequencies
with the MTHFR A1298C allele, and the last article was removed because the birth outcome was
asthma and allergy unrelated to death of the offspring (and therefore, unrelated to fitness). This
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left a total of twenty-nine relevant articles that meet inclusion criteria and listed all the required
variables (Figure 2). The literature search yielded studies where the observed outcome was
Down Syndrome, recurrent pregnancy loss, unexplained female infertility, preterm birth,
preeclampsia, neural tube defect (NTD), and spontaneous abortion.
After grouping the data together by birth outcome, those groups without enough
participants with comparable data were excluded. Articles included for analysis were studies
where the observed birth complication was Down Syndrome (DS), recurrent pregnancy loss
(RPL), and neural tube defects, (NTD). These birth outcomes were chosen due to the frequency
at which they appeared in the literature: they returned the greatest amount of data that would
allow for the multivariate analysis needed to understand the relationship between the mutation
and pregnancy outcomes. I was able to amass a large number of total participants. In total, the
sample size is n = 2605 individuals (1111 cases and 1494 controls). In all of the included
literature, each study is investigating the association of the MTHFR C677T mutation (by way of
maternal genotype) in pregnant women and the birth outcome of the offspring.
The control women were defined in the literature as healthy women who were
primiparous (at minimum) and gave birth absent of any obstetrical complications. They were
recruited either during pregnancy or while at a routine follow-up appointment with their
healthcare provider shortly after giving birth (Table 1). Control participants were recruited at the
same facilities that case participants were identified and treated. The case women for the Down
Syndrome group were defined as women who are less than 35 years old, were pregnant at the
time of recruitment into the study and gave birth to a child with Down Syndrome; the case
women comprising the RPL group were defined as women with a history of two or more
unexplained instances of loss of pregnancy and were pregnant at the time of study (Table 2).

22

Exclusion criteria for the RPL group specified that women were ineligible for the case study if
they had uterine abnormalities, presence of protein C, protein S, antithrombin deficiency, known
reason for recurrent miscarriage, or if she or her partner had chromosomal abnormalities.
The case women of the NTD group had a broader range of inclusion criteria. Half of the
literature included only mothers who were pregnant at the time of recruitment into the study and
then gave birth to a child with ambulatory spina bifida (Christensen et al., 1999) or spina bifida
occulta (Caroline L. Relton et al., 2004), and excluded mothers who were also pregnant at the
time of study, but whose child was born with a syndromic NTD (Table 2). The other half of the
included literature incorporated women who were pregnant at the time of recruitment into the
study and who then gave birth to a child with any form of NTD, syndromic or non-syndromic
(Deb et al., 2011; Y. Wang et al., 2015a). These include mothers whose child was born with
anencephaly, encephalocele, myelomeningocele, spina bifida, spinal dysraphism, or a
combination of one or more of these NTDs (Table 2).
Maternal age was reported for each included study, but many were reported as ranges. In
order to optimize the data analysis, the average age of the participants from each study was taken
and converted to a discrete variable (Table 3). The ethnicity of the participants was also collected
as a separate variable. Due to the differences in the mutation’s frequency by ancestral gene pool,
population frequency by ethnicity is a common approach to cataloguing allele frequencies,
especially within heterogenous populations (Candito et al., 2008; Christensen et al., 1999).
Reporting results by ethnicity can also aid in measuring change of the frequency within the
population over time. If ethnicity was not reported within the original data and could not be
found through government population demographic websites, nationality was used as a proxy.
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Table 1: Control Data by Group
Source

Geographic
Location

Ethnicity

CC

CT

TT

p

Q

HWE

Individual
Folate
Supplementation
No

Dietary
Folate

Yes

National
Folate
Fortification
Yes

Christensen
et al.

SE Canada

European
Descendant

44

36

10

0.6889

0.3111

Deb et al.

N. India

149

64

9

0.8128

Wang et al.

N. China

Multiethnic:
Majority
Punjabi
Han Chinese

0.1872

Yes

No

Yes. Amount
varied.

High

96

45

159

0.395

0.605

No

No

Yes. Amount
varied.

NTD
Group:

289

145

168

Makino et
al.

Japan

Yamato

29

32

15

0.5921

0.4079

Yes

No

None

Wolski et
al.

Poland

Polish

201

164

35

0.7075

0.2925

Yes

No

400mg/day

RPL Group

230

196

50

High

Maternal
Age

Diagnosis
Group

3.5

NTD

1

NTD

1

NTD

1

RPL

2.5

RPL

Rai et al.

India

Multiethnic/
Gujarati

124

39

2

0.8697

0.1303

Yes

No

Low

1.5

DS

Coppede et
al.

Italy

Italian

39

54

18

0.5946

0.4054

Yes

No

High

2

DS

DS Group:

163

93

20
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Table 2: Case Data by Group
Source

Geographic
Location

Ethnicity

CC

CT

TT

p

q

HWE

Individual
Folate
Supplementation
None

Dietary
Folate

Yes

National
Folate
Fortification
Yes

Christensen
et al.

SE Canada

European
Descendant

24

27

11

0.6048

0.3952

Deb et al.

N. India

80

25

6

0.8333

Relton et
al.

N. England

Multiethnic:
Majority
Punjabi
English

31

36

15

Wang et al.

N. China

Han
Chinese

31

73

40

NTD
Group:

166

161

72

Maternal
Age

Diagnosis
Group

4

NTD

0.1667

Yes

No

Yes. Amount
varied.

High

1

NTD

0.5976

0.4024

Yes

No

None

5.5

NTD

0.4688

0.5313

Yes

No

Yes, amount
varied

1

NTD

2.5

RPL

2.5

RPL

Makino et
al.

Japan

Yamato

56

55

14

0.668

0.332

Yes

No

None

Wolski et
al.

Poland

Polish

165

153

41

0.6727

0.3273

Yes

No

400mg/day

RPL
Group

221

208

55

High

Coppede et
al.

Italy

Italian

20

43

16

0.5253

0.4747

Yes

No

High

2

DS

Rai et al.

India

Multiethnic/
Gujarati

97

40

12

0.7852

0.2148

No

No

Low

1.5

DS

DS Group:

117

83

28
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Table 3: Age Range Reclassification to
Discrete Variable

Age:
20-22.49
22.5-25
25.1-27.49
27.5-30
30.01-32.49
32.5-35
35.1-37.49
37.5-40
40.1-42.49
42.5-45
45.1-47.49
47.49-50
50.1-52.49

Group
1
1.5
2
2.5
3
3.5
4
4.5
5
5.5
6
6.5
7

The recorded ethnicities of participants can be found in
Tables 1 and 2, and the geographic spread of the data collected
can be found on Figures 3 and 4. These figures show the
frequency of the two alleles in a pie chart. It is clear that all of the
data come from the Northern Hemisphere. The T allele is virtually
absent in Africa and the South Pacific, and the few studies which
have been done in South American Indigenous groups do not
report it (Reyes et al., 2021).

Figure 3: Geographic Spread of Control Data

Figure 4: Geographic Spread of Case Data

26

Data Analysis
All analyses were conducted using Statistical Analysis System (SAS) Copyright © 2016
by SAS Institute Inc., Cary, NC, USA. Case data, that is women who gave birth to a child with
DS or NTD or who conceived after suffering from RPL, were conducted separately, in three data
subsets. These data are not comparable, as the birth outcome in group is different. At first,
control data from each diagnosis group was done separately. Upon realizing that similar results
were returned, the control data from all studies included were grouped together, as they all meet
the same inclusion criteria (see Data Collection) and analysis was conducted on the full controls
data set. After completing descriptive statistics and examining our data groups using simple
frequency distributions, several logistic regression models were computed for to each data set.
We determined that the best fitting model was ordinal logistic regression. Here the dependent
variable is number of births by CC, CT, and TT genotypes. The following variables were
included as independent predictor variables: presence/absence of folate supplementation,
presence/absence of folate-supplemented foods, and maternal age (as explained above).
The general null hypothesis is that the model does not explain variation of the dependent
variable. Each model was evaluated with three built-in inferential tests (the likelihood ratio,
score test, and Wald test) to determine if the logistic regression provided an improvement over
the baseline intercept-only value. The parameters of each model were then individually evaluated
by looking at their own p value and the confidence limits of their respective odds ratio (Peng et
al., 2002). The odds ratio of a single predictive variable explains its effect on the dependent
variable, holding all other predictive variables constant. This is an iterative process that requires
entering variables, removing them, and evaluating each model for each data subset (controls and
cases for each birth outcome). Odds ratios for the dependent variable cannot be calculated in
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logistic regression. To determine the odds and relative risk lent by maternal genotype in the birth
outcome, a Chi square test, odds ratio, and relative risk was computed for each diagnosis group
to compare the probability of giving birth to a child without congenital defects (in the NTD and
DS groups) or to compare the probability of achieving pregnancy (in the RPL group). Cases and
controls were included within the same odds ratio; since an odds ratio is determining the odds
that an event will occur, both women who had a negative birth outcome (cases) and those who
had no obstetrical complications (controls) must be included in the same test.
Upon realizing that the same results were obtained for each individual control data
subsets (the data were telling the same story), the analysis was repeated for the entire control
dataset. Because all controls meet the same inclusion criteria and had almost the same variables
measured across all studies, all of the control data were comparable and could be grouped into
one large dataset. The same progression of analysis was completed with the large control dataset:
logistic regression with the three inferential statistic tests, the Wald chi-square test for
significance, and the odds ratio of the predictor variables (maternal age and folate status).
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RESULTS
Down Syndrome Group
DS Case Subset
Table 4a: Frequencies of Down Syndrome Case Subset by Age and Genotype

Table of Genotype by Age
Age
Genotype
1.5
2
2.5
97
111
31
CC
17.6
20.15
5.63

Total
239
43.38

CT

40
7.26

119
21.6

88
15.97

247
44.83

TT

12
2.18

16
2.9

37
6.72

65
11.8

149
27.04

246
44.65

156
28.31

551
100

Total

Table 4b: Chi-Square Results of Down
Syndrome Case Subset Demonstrating
Significance

Statistic

DF

Value

Prob

ChiSquare

4 78.7649 <.0001

Likelihood
Ratio ChiSquare

4 80.1582 <.0001

This data subset includes only women who gave birth to a child with Down Syndrome
(Coppede et al., 2006; Rai et al., 2006). In these studies, age groups 1.5, 2, and 2.5 were
represented. Table 4a shows the number of Down Syndrome (DS) births by maternal age and
genotype. 274 participants were deleted due to missing values for one or more variables. The
Chi-square and likelihood ratio tests reject the null hypothesis of no association between
genotype and age (Table 4b). Here, the outcome is DS birth, maternal genotype is the dependent
variable, and age is an independent predictor variable. These data suggest that the outcome of
pregnancy is affected by maternal genotype. No independent variable contributed significantly to
the model including age, where the point of reference is the TT genotype (Table 4c).
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Table 4c: Results of DS Case Subset Logistic Regression Demonstrating Genotype Contribution to Outcome

Analysis of Maximum Likelihood Estimates
Parameter

DF Estimate Standard
Wald Pr > ChiSq
Error Chi-Square

Intercept

CC

1

0.4025

0.1226

10.7744

0.0010

Intercept

CT

1

2.1852

0.1993

120.1930

<.0001

Here, TT women have the lowest predicted fecundity. CC women have slightly greater fecundity
than do TT women (p = 0.001), while CT women are predicted to have the highest fecundity (p <
0.0001).

DS Control Subset
Table 5a: Frequency of DS Control Subset by Age and Genotype

Table of Genotype by Age
Genotype
Age
1.5
2
2.5
CC

CT
TT

Total

Total

124
18.42

113
16.79

66
9.81

303
45.02

39
5.79
2
0.3

243
36.11
75
11.14

0
0
11
1.63

282
41.9
88
13.08

165
24.52

431
64.04

77
11.44

673
100

Table 5b: Chi-Square Results of Down Syndrome
Control Subset Demonstrating Significance

Statistic
DF Value
Prob
Chi4 186.416 <.0001
Square
Likelihood
4 224.736 <.0001
Ratio ChiSquare

Frequency Missing = 118

The DS controls subset includes the women recruited within the DS studies who did not
give birth to children with Down Syndrome. These women were defined as controls within the
source studies and gave birth to a child with no obstetrical complications (Coppede et al., 2006;
Rai et al., 2006). In this group, 118 participants were deleted due to missing values and only age
groups 1.5, 2, and 2.5 are represented in this sample (Table 5a). Here, the dependent variable is
again maternal genotype and age is an independent predictor variable. Age contributed to the
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model in addition to maternal genotype (Table 5b), where the point of reference is the TT
genotype.
Table 5c: Results of DS Control Subset Logistic Regression Demonstrating Genotype Contribution to Outcome

Analysis of Maximum Likelihood Estimates
Parameter

DF Estimate Standard
Wald Pr > ChiSq
Error Chi-Square

Intercept

CC

1

6.5419

0.9230

50.2306

<.0001

Intercept

CT

1

9.0107

1.0008

81.0673

<.0001

1

-3.6103

0.5281

46.7408

<.0001

Age

The model is highly significant (X2 = 186, df = 4, p < 0001) and shows that CT women are
predicted to have a greater fecundity than CC or TT women (p < 0.001), though CC women are
also predicted to have higher fecundity than TT women, who are modeled to have the lowest
fecundity. For all women, the effect of age is to lower predicted fecundity by 3.6 units, where the
unit is a categorical variable constructed for this study. As age increases by one unit, fecundity
will decrease by 3.61.

Odds Ratios
A Chi square test, odds ratio, and relative risk was computed to compare the probability
of giving birth to a child with DS to determine the risk lent by different maternal genotypes. All
DS case and control individuals minus those missing data for any variables are included in the
odds ratio estimates (Coppede et al., 2006; Rai et al., 2006). Upon initial comparison, no
significant relationships were found between variables (data not shown). Due to the size of the
data set, the data was then broken up into the discrete age categories. At this level of analysis,
several associations were found, but no patterns emerged. There does not appear to be any
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systematic difference between birth outcomes (mothers who gave birth to a child with or without
DS) by maternal genotype.

Recurrent Pregnancy Loss Group
Table 6a shows the number of pregnancies within the group of women who previously
suffered from RPL by maternal age and genotype; in other words, the case group (Makino et al.,
2004; Wolski et al., 2017). Results indicate that genotypes and age are not independent (Table
6b). Table 7a shows the number of pregnancies within the control group, which is comprised of
women who achieved pregnancy without history of RPL or spontaneous abortion and gave birth
to a healthy child in the absence of obstetrical complications (Makino et al., 2004; Wolski et al.,
2017). Within the control group, an interaction between genotype and age is also present, even
though the age categories are not the same as those of the case participants (Table 7b). At this
point, it was concluded that the interaction among age and genotype was equal in both cases and
controls.
Table 6a: Frequency of RPL Case Subset by Age and Genotype

Genotypes
CC

Age
1.5
104
9.56

2
75
6.89

2.5
247
22.7

Total
426
39.15

Table 6b: Chi-Square Results of RPL Case
Subset Demonstrating Significance

Statistic
CT

208
19.12

6
0.55

240
22.06

454
41.73

TT

59
5.42

3
0.28

146
13.42

208
19.12

Total

371
34.1

84
7.72

633
58.18

1088
100

32

DF

Value

Prob

ChiSquare

4 127.9820 <.0001

Likelihood
Ratio ChiSquare

4 131.1489 <.0001

Table 7a: Frequency of RPL Control Subset by Age and Genotype

Genotypes
CC

CT

TT

Total

2
107
9.43

Age
2.5
6.5
241
94
21.23
8.28

Total
442
38.94

34
3

286
25.2

156
13.74

476
41.94

15
1.32

137
12.07

65
5.73

217
19.12

156
13.74

664
58.5

315
27.75

1135
100

Table 7b: Chi-Square Results of RPL Control
Subset Demonstrating Significance

Statistic

DF

Value

Prob

ChiSquare

4 71.2675 <.0001

Likelihood
Ratio ChiSquare

4 69.9533 <.0001

Table 8a: Frequency of RPL Cases and
Controls with Folate Supplementation
by Genotype

Genotypes

Sample
Size

CC

85

CT

32

TT

15

We tested if there was a difference in genotype
frequency between cases and controls and found that there
was no significant difference between the two subsets (data
not shown; X2 = 0.0123; df = 2; p=0.99). For that reason, the case and controls data subsets were
merged into one dataset to investigate the null hypothesis that maternal genotype does not affect
the ability to become pregnant. With this larger sample, folate supplementation was held
constant, so participants whose access to folate was unknown were eliminated. That decreased
the sample size considerably (Table 8a). To obtain odds ratios for these participants, I performed
an odds ratio calculation using the proc freq procedure of SAS for two genotypes and for cases
and controls. I show in Table 8b (where none of the included women supplemented with folate)
and 8c (where all included women supplemented with folate) the number of participants by
genotype and case or control categories. Remember that case women are those who suffered
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from RPL prior to becoming pregnant, while control women did not have any history of RPL and
Table 8b: Frequency by CC and CT Genotype of RPL Cases and
Controls with No Folate Supplementation

No Folate Supplementation
Genotypes
Cases
control
CC
56
29
CT

0

32

Total

47.86

52.14

Total
85
72.65%
32
27.35%
n=117

Table 8c: Frequency by CC and CT Genotype of RPL Cases and
Controls with Folate Supplementation

Individual Folate
Supplementation. Cases
Genotypes
CC
165

CT

had a normal pregnancy.

The chi-square is highly significant (X2 =
40.43, df = 1, p < 0.0001). The odds ratio
is not computed due to the 0 value for CC
cases (Table 8b). With supplementation
(Table 8c), CT women recorded as cases
are not significantly different from that of
CC women. I then proceeded to compute

control

Total

201

366
53.59%

45.08% 54.92%
153
164

the odds ratio of CC and TT women in
cases and control groups, controlling for
supplementation. Results are shown in

317
46.41%

Tables 8d and 8e. As we had seen in the

Total
46.56%

53.44% n=683

previous comparison, TT women are only

predicted to be cases when supplementing (X2 = 22.45, df = 1, p < 0.0001). Otherwise, TT
women are more likely to be controls, or women who did not suffer from RPL (X 2 = 1.98, df = 1,
p = 0.158).
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Table 8d: Frequency by CC and TT Genotypes of RPL Cases and Controls with No
Folate Supplementation

No folate
supplementation.

Group
Cases

Control

Total

56

29

85
85

Genotypes
CC
100

65.91

0

15

0

34.09

TT

The results of the comparison
between CC and TT
participants also indicates that
both heterozygous CT and

15

homozygous TT individuals
who receive folate
supplementation have a higher

Total

56

44

100

Table 8e: Frequency by CC and TT Genotypes of RPL Cases and
Controls with Folate Supplementation

Folate
Supplementation
Genotypes

Group

probability of being cases.

These analyses indicates that folate

Cases

Control

Total

supplementation in women who have had

165

201

366
82.81

multiple recurrent pregnancy losses may

CC

be helpful in completing a pregnancy.
41

35

76
17.19

206
46.61

236
53.39

442
100

TT
Total

Neural Tube Defect Group
NTD Case Subset

Table 9a: Frequency of NTD Case Subset by
maternal genotype.

The NTD case subset includes mothers who gave
birth to a child with one or more neural tube defects
(Christensen et al., 1999; Deb et al., 2011; Caroline L.

Response Profile
Ordered Genotype
Total
Value
Frequency
1 CC

252

Relton et al., 2004; Y. Wang et al., 2015b). Here, the

2 CT

239

modeled outcome is the birth of children with neural tube

3 TT

94
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defects by the dependent variable of maternal genotype and the independent variable folate
supplementation. Participants without reported information for their folate supplementation and
age categories were excluded, which reduced the sample sizes (Table 9a). This was done because
of the known importance of folate in preventing NTD.
Table 9b: Results of NTD Case Subset Logistic Regression Demonstrating Genotype, Insolation, and Folate Supplementation
Contribution to Outcome

Analysis of Maximum Likelihood Estimates
Parameter

DF Estimate

Intercept
Intercept
Folate
Supplementation

CC
CT

Standard
Error

Wald
Pr > ChiSq
Chi-Square

1
1

0.6465
2.7545

0.163
0.1983

15.7274
192.989

<.0001
<.0001

1

-1.02

0.1984

26.4391

<.0001

Table 9c: Log Odds Ratio Estimate of Folate Supplementation's Effect in Birth Outcome

Odds Ratio Estimates
Effect

Point Estimate

Folate
Supplementation

95% Wald
Confidence
Limits

0.361 0.244

0.532

In this subset, TT women are predicted to have the lowest fecundity, meaning they are modeled
to have the fewest instances of birth of children with NTDs. CC women are predicted to have
slightly higher fecundity than TT women, indicating that the risk of giving birth to a child with
NTD is slightly higher (p < 0.0001), while CT women are predicted to be much more fecund
than TT women (p < 0.0001). This indicates that CT women are predicted to have the highest
instances of NTD birth when maternal genotype is the dependent variable. Folate
supplementation was predicted to lower the log odds of giving birth to a child with one or more
NTD. I calculated an odds ratio of 0.361 with a 95% confidence interval of 0.244-0.532,
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indicating that the log odds of giving birth to a child with NTD is 36% lower when
supplementing with folate (holding all other variables constant).

NTD Control Subset
This subset of NTD Controls is comprised of women who gave birth to a child in the
absence of any obstetrical complications, where the children born did not have any NTDs or any
other congenital defect (Christensen et al., 1999; Deb et al., 2011; Y. Wang et al., 2015b). The
participants included in the control subset are included in Table 10a, which shows the number of
births by maternal genotype. Here, the modeled outcome is the birth of children without NTDs
by the dependent variable of maternal genotype and the independent variable folate
supplementation. Again, participants without recorded folate supplementation or age values were
removed, which reduced the number of participants included. The logistic regression model for
this group of controls is shown in Table 10b.
Table 10a: Frequency of NTD Control Subset
by Genotype

Response Profile
Ordered genotype Total
Value
Frequency
1

CC

289

2

CT

145

3

TT

178

Table 10b: Results of NTD Control Subset Logistic Regression Demonstrating Genotype, Insolation, and Folate Supplementation
Contribution to Outcome

Analysis of Maximum Likelihood Estimates
Parameter
Intercept
Intercept
Folate Supplementation

DF Estimate
CC
CT

1
1
1

0.2398
1.4402
1.2778
37

Standard
Error
0.2035
0.2134
0.28

Wald
Chi- Pr > ChiSq
Square
1.3876
0.2388
45.5655
<.0001
20.8194
<.0001

Figure 10c: Log Odds Ratio Estimates of Folate Supplementation’s
Effect on Birth Outcome

Odds Ratio Estimates
Effect

Point Estimate

Folate
Supplementation

3.589

95% Wald
Confidence Limits
2.073

6.213

Once again, TT women are predicted to have the lowest fecundity. CC women are
predicted to have slightly higher fecundity than TT women (a non-significant difference, p =
0.239) while CT women are predicted to have much greater fecundity than do TT women (p >
0.0001). Furthermore, folate supplementation was a significant predictor in this model. As folate
increases by one unit, the predicted fecundity of all women increases by 1.28. I calculated an
odds ratio of 3.589 with a 95% confidence interval of 2.073-6.213 indicating that the log odds of
giving birth to a child without NTD or any other congenital defect is 3.5 times greater when
mothers take a folate supplement (Table 10c).

Odds Ratio Estimates
I then calculated chi-square tests and odds ratios to quantify the differences seen between
the maternal genotypes in the previous logistic regression models. Here, cases and controls of
two genotypes are considered at the same time as both the negative and positive outcome must
be present to calculate an odds ratio. Without considering any independent variables, there are
significant differences between the effects of the maternal genotypes. The incidence of NTD
birth is significantly different between the three genotypes.
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Table 10d: Frequency of CC and TT Genotypes of the NTD Group with Cases and Controls

Case

Control

Total

CC

86

193

279

TT

66

19

85

Total

152

212

364

When comparing CC and TT cases (those who gave birth to a child with NTD) vs CC
and TT controls (those whose child was born without congenital defects), we find that 77.65% of
TT women gave birth to a child with NTD. These genotypes are significantly different (X2 =
58.729, df = 1, p < 0.0001).The odds ratio of 0.13 with a 95% confidence interval of (0.07250.2268) indicates that that CC women are 13% less likely to have an NTD than TT women. The
relative risk of 3.1 with a 95% confidence interval of 2.04-4.63 indicates that the control group is
comprised of a far greater amount of CC women than TT women. These results indicate that TT
women are more likely to give birth to an NTD child than CC women.
The differences between CC and CT women within the NTD group are also significant.
The odds ratio of 0.32 indicates that CC women are 32% less likely than CT women to have a
child with NTDs. CT and TT women are also significantly different in the instance of NTD birth.
The odds ratio of 3.27 with a 95% confidence interval of 2.31-4.64 indicates that CT women
have 3.2 times higher odds of giving birth to a child with NTD than TT women.
Table 10e: Odds Ratio and Relative Risk, CT vs. TT Women from NTD Literature

Odds Ratio and Relative Risks
Statistic

Value 95% Confidence Limits

Odds Ratio

0.3915

0.2210

0.6936

Relative Risk (Column 1) 0.7422

0.6337

0.8692

Relative Risk (Column 2) 1.8956

1.2415

2.8944

39

When considering folate supplementation, interesting relationships become apparent. I
considered the NTD source material where individuals did supplement with folate separately
from those that did not. When considering women who did not supplement with folate
(Christensen et al., 1999; Caroline L. Relton et al., 2004), TT women had 3.9 times higher odds
of giving birth to a child without NTD than did CC women (OR = 3.9394, 95% CI = 1.248911.5049).
Table 10f: Chi-Square Tables Demonstrating CT Women's Higher Probability for NTD Birth When Supplementing with Folate

Case

Control

Total

Case

Control Total

CC

148

245

393

CT

187

109

296

CT

187

109

296

TT

88

168

256

Total

35

364

689

Total

275

277

552

When women were supplementing with folate, we found that the effects of folate
supplementation do not seem to reduce the number of NTD births in CT women. The relative
risk value for case women of 0.5961 indicate that CC women are much less likely to have a child
with NTD than are CT women when supplementing with folate (R = 0.5961, 95% CI = 0.51100.6954). Again, CT women were much more likely to give birth to children with NTDs than TT
women (R=1.8378, 95% CI = 1.5194-2.2231). However, there was no distinguishable difference
between the probability of having a child with NTD between CC and TT women who took folate
supplements. In the logistic regression models, we found that folate supplementation reduced the
likelihood of giving birth to a child with NTD. Here, we found that folate supplementation may
aid in the prevention of NTD for TT women to a greater extent than it does for CT women.

Preliminary Conclusions
Through these initial tests, I have concluded the following:
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1. In all cases presented within this study, TT women have the lowest predicted fecundity
followed by CC women.
2. Except for one comparison, CT women always had a significantly higher number of
pregnancies. This was true even when controlling by age, folate supplementation, or any
other independent predictor variable. Sometimes these women had more than twice the
number of pregnancies than CC women did.
3. The results were virtually identical for control and case groups.

Therefore, I proceeded to perform the same progression of analyses for all control women by
combining the three control subsets into one large dataset. These are comparable data: all
participants were women who did not experience RPL and gave birth to a child with no adverse
health conditions present. The aim of this secondary analysis is to ask the following question: Is
it possible that CT women have higher numbers of poor pregnancy outcomes (RPL, DS, and
NTD) because these women also have higher numbers of pregnancies? In short, are CT women
more fecund? If this is the case, then this may be the natural selective mechanism explaining the
high frequency of this otherwise negative polymorphism.

Results of Control Dataset Analysis
This is the exploration of the full control dataset,
which includes all control participants from each study
included in this review (Table 1). Analysis was restricted
to women whose age and folate status was known, which
reduced sample size (Table 11a).
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Table 11a: Sample Size of Control Dataset
Where Age and Folate Supplementation Status
are Known

Response Profile
Ordered Genotypes
Total
Value
Frequency
1 CC

178

2 CT

96

3 TT

24

Table 11b: Results of Control Dataset Logistic Regression Demonstrating Genotype and Age Contribution to Outcome

Analysis of Maximum Likelihood Estimates
Parameter
Intercept
Intercept
Age

CC
CT

DF

Estimate

Standard
Error

Wald
Chi-Square

Pr > ChiSq

1
1
1

2.0408
4.216
-1.3097

0.3587
0.4364
0.264

32.3672
93.3109
24.6034

<.0001
<.0001
<.0001

Once again, TT women are likely to have the lowest fecundity, CC women are predicted to have
greater fecundity over TT women, while CT women are likely to have the highest fecundity,
holding age constant (Table 11b). In summary, the data analysis indicates that CT women are
likely to be more fecund than either CC or TT women. If CT women have greater numbers of
birth defects or are more likely to suffer from RPL, it is also because these women have a greater
overall number of pregnancies.
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DISCUSSION
The results show that CT women are more fecund than CC and TT women, yet also more
commonly suffer from RPL or give birth to a child with NTD and DS. The current clinical
literature emphasizes that the TT genotype will face most drastic effects of the mutation by way
of higher homocysteine, lower methylation status, and lower levels of 5-methylTHF, and
generally states that CT women face these effects to a significantly lower degree (Friso et al.,
2002; Liew & Gupta, 2015; Servy et al., 2018). The results found within this study demonstrate
that the effects leveraged by the mutation are still enough to contribute lowered fertility and poor
birth outcomes. Moreover, this pattern signals that some aspect of the phenotype portrayed in CT
individuals is being selected for. Greater fecundity of CT women may explain part of this
selective force, though this is not a conclusive statement. The results of this study also show that
CT women are more likely to suffer from RPL or give birth to a child with NTD or DS. I have
concluded that this greater number of fertility and pregnancy issues arise as a result of the
increase in total pregnancies in CT women (Table 11b).
The results of this study also show that folate supplementation decreased the odds of
pregnancy resulting in NTD for TT women but did not decrease the probability of pregnancy
resulting in NTD for CT women (Table 9b, 10f). It also appears to increase the probability of a
successful pregnancy in women who have suffered from RPL, but otherwise was not a
significant contributor to the fecundity of other groups within this study. While supplementation
with folic acid is the current recommended practice upheld by the CDC and most clinical
physicians, there is a growing body of literature that suggests that supplementation with 5-
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methylTHF is just as effective for wild-type individuals and is safer and more effective for
heterozygous or homozygous individuals (Clément et al., 2020; Crider et al., 2011; Lucock &
Yates, 2005, 2009; Plumptre et al., 2015; Servy et al., 2018). The CDC’s website cites that folic
acid is the only supplement known to prevent NTD and should therefore continue the
recommendation that all pregnant women and those trying to become pregnant should
supplement with folic acid.
Our results suggest that this is not a universal truth for all populations. A large, blind
study comparing the efficacy of folic acid versus 5-MTHF in preventing NTD should be
completed in order to better understand the relationship between folates and NTD. Furthermore,
the CDC should reevaluate the literature and consider amending their statement on folic acid
supplementation. Their website cites literature that is outdated and seemingly biased. Neither
their web page devoted to the MTHFR mutation and folate supplementation, nor the citations
referenced show any clinical literature that has demonstrated the negative affects leveraged by
folic acid supplementation or the efficacy of 5-MTHF supplementation. Their current statement
simply no longer matches the current literature and reads as follows:
“You might have read or heard that folic acid is not safe if you have one or two
copies of the MTHFR C677T variant. This is not true. Even if you have one or
two copies of the MTHFR C677T variant, your body can safely and effectively
process the different types of folate, including folic acid.” (CDC,
https://www.cdc.gov/ncbddd/folicacid/mthfr-gene-and-folic-acid.html)

Limitations
The use of previously conducted data is generally considered a limitation due to the
limited knowledge that is made public. Furthermore, many of the studies first discovered through
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the literature search could not be included due to poor study design. Thirty-five articles failed to
include folate supplementation status or report maternal age and thus could not be included
(Figure 2). Seven more articles could not be included because the study design included multiple
birth outcomes within a single case group.
Maternal age and folate supplementation status were included in this study as
independent predictor variables due to the known ways that folate status and maternal age can
impact pregnancy and fertility. For example, it is generally accepted that lower folate can make
conception more difficult or may result in adverse birth outcomes and increasing maternal age
may lead to the same results. However, the most common variable missing from literature was
the folate status of the women included. Less commonly, maternal age was not included. The
results concluded in this study further show that genotype cannot be considered in contributing to
the birth outcomes studied alone, and maternal age and folate supplementation status should
always be included to fully understand the interactions at play.
A significant observation in the NTD Group data collection was individuals who gave
birth to a child with syndromic NTD are often excluded as part of the study design. Frequently,
studies on the association of NTD and the mutation are limited only to spina bifida or spina
bifida occulta and exclude all other forms of NTD or any offspring who are deceased due to
syndromic NTD. The result of these exclusions is an underreporting of the totality of the way the
MTHFR C677T mutation can contribute to NTD. It also impacted the data collected in this
paper; only half of the articles included in this study allowed for the inclusion of participants
who gave birth to children with syndromic NTD.
Lastly, the clinical nature of this literature leads to the frequent misclassification of
ethnicity. Ethnicity is often listed in racial terms (e.g., “Caucasian, Black, White”) or nationality
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(e.g., “Polish” or “Czech”) rather than the historical or ancestral ethnic group of individuals.
These terms are not descriptive and tell us nothing about the historical allele frequency within
the population or whether to expect the allele frequency to be high or low in that group. In some
instances, when ethnicity was simply listed using a broad racial, literature had to be excluded due
to the highly heterogenous nature of the location from whence they came. For example, a South
African paper documenting the allele frequency and instance NTD within the population cited
the participant population as Black rather than one of the many ethnic groups found in South
Africa (Ubbink et al., 1999). Furthermore, these terms continue the false narrative of “race-based
medicine,” or the idea that certain racial groups are predisposed to certain health conditions
based on race alone. As we fundamentally agree that race is a constructed identity and is in no
part inherently biological, clinicians must report ethnicity data more responsibly.

Relevance to Applied Anthropology
The current literature includes a plethora of studies on the association of the mutation
with male infertility and fetal death but fails to focus on the facilitator and carrier of the
pregnancy. One of the goals of this study was to place focus on this erased population by only
collecting data pertaining to mothers and carriers of the pregnancy. It is important to note that
because all data collected for the use in this paper are from previously conducted clinical studies,
the data most-likely only represent cis-gendered women. Though many biologists and biological
anthropologists alike agree that chromosomal or genital-based sex assignment at birth is not what
defines one’s sex or gender identity, none of the reference papers included in this review make
any mention of including patients other than those traditionally considered women.
That is, only those who were assigned the female sex at birth can be assumed to have
been included in the reference data. It should be noted that people of many genders experience
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pregnancy and are also more likely to have inadequate access to health care, face discrimination
from health care providers, and may not seek care due to fear of stigma (Moseson et al., 2020).
While it was a goal of this study to encompass more experiences than solely those of cisgendered women, it was not possible in this setting. Nonetheless, in my future applied
dissertation research among the Bribri and Cabecar of Costa Rica, I intend to foster an
environment which celebrates and includes genders outside the Western binary.
Additionally, the clinical nature of the data available has excluded Native and Indigenous
populations. As previously noted, the highest frequencies found in the world are recorded in
Mexico and Central American Indigenous populations. Sadly, there are extremely limited data
available for the clinical ramifications of the T-allele in Indigenous populations, particularly in
Mexico and Central America due to the isolated nature of many Indigenous communities.
Isolated communities have limited access to fertility clinics and biomedical hospitals, which
largely exclude them from the available literature. Moreover, these populations have not been
acknowledged in the history of the research of this polymorphism. Most of the studies on the
clinical outcomes of this mutation have focused on European (Mayor-Olea et al., 2008b) or East
Asian (Y. Wang et al., 2015b) populations. We do not know if Native American communities in
their ancestral lands with their own diet suffer of pathology related to the mutation. However,
their absence from the clinical literature is a loud reminder of unequal representation, particularly
of Native women.
Furthermore, times of epidemiological transition in Mexican and Central American
indigenous communities may amplify the effects of the mutation. As neoliberalism expands and
the need to enter the cash economy increases, it is a concern that Native and Indigenous folks
with the mutation may see worsened health outcomes. Facets of assimilated Western life that
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contribute to the morbidity of chronic diseases, such as a sedentary lifestyle and loss of
traditional diet, will only intensify the effects of the mutation. Furthermore, common health
outcomes such as cancer, obesity, cardiovascular disease, and infertility are often compounding
and require long-term healthcare. These are chronic conditions which in Western society are
frequently perceived as resulting from one’s own poor lifelong health skills.
For example, the development of obesity in an individual in the United States is not
judged through the consideration of the economic or systemic barriers that may decrease access
to healthy foods, a safe neighborhood to walk or run in, or the time an individual must spend to
generate enough income to stay alive. The development of obesity in an individual is instead
judged as that individual’s fault regardless of all other factors. It is concerning to think that this
assumption may be passed onto other individuals who are being forced by neoliberalism to
abandon their sovereignty and live a lifestyle that may be damaging to their health.
Applied research to investigate the role of the mutation in the Native and Indigenous
communities of Mexico and Central America must be completed. Again, I iterate that these
populations show the highest frequencies of this mutation anywhere in the world, yet the
phenotypic effects of the mutation have been largely unstudied within these populations (Reyes
et al., 2021). Individuals have a right to autonomy over their own health and should be aware of
the ways this mutation may be affecting their lives.
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CONCLUSIONS
Since its discovery in the late 1990s, the MTHFR C677T mutation has been the focus of
many geneticists, physicians, and biologists due to its wide global distribution and many
associated health effects, caused by hyperhomocysteinemia, lower methylation, and lower levels
of circulatory folate. Evolutionary theory leads us to predict that populations have evolved and
maintained high frequencies of a deleterious allele in their homelands because somehow in their
niche the allele is not deleterious. The results of this study indicate that the observed higher
fecundity of CT women may explain part of this evolutionary advantage. However, the
relationship between folates and adverse birth outcomes must be further explored.
This study has closed a fraction of the gap in knowledge at the nexus of population
genetics, reproductive justice, Indigenous rights, and evolutionary biology. Nevertheless, before
more applied work can be completed, baseline investigatory work such as this review was
necessary to first quantify the way populations react to selection.
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